Mirum Pharmaceuticals, Inc. Shareholders' Equity
Mirum Pharmaceuticals, Inc. (MIRM) had Shareholders' Equity of -$10.42 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-05
- 2026-06-30: Stockholders' Equity Attributable to Parent -$10.42M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $242.49M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $314.69M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $292.05M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | -$10.42M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $242.49M 10-Q · filed 2026-08-05 |
| 2025-12-31 | $314.69M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $292.05M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $255.16M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $233.26M 10-Q · filed 2026-08-05 |
| 2024-12-31 | $225.64M 10-Q · filed 2026-08-05 |
| 2024-09-30 | $232.02M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $228.99M 10-Q · filed 2025-11-04 |
| 2024-03-31 | $234.60M 10-Q · filed 2025-11-04 |
| 2023-12-31 | $248.67M 10-K · filed 2026-02-25 |
| 2023-09-30 | $269.08M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $78.61M 10-Q · filed 2024-11-12 |
| 2023-03-31 | $141.15M 10-Q · filed 2024-11-12 |
| 2022-12-31 | $142.04M 10-K · filed 2026-02-25 |
| 2022-09-30 | $169.30M 10-Q · filed 2023-11-02 |
| 2022-06-30 | $110.69M 10-Q · filed 2023-11-02 |
| 2022-03-31 | $108.93M 10-Q · filed 2023-11-02 |
| 2021-12-31 | $120.21M 10-K · filed 2025-02-26 |
| 2021-09-30 | $56.40M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $95.74M 10-Q · filed 2022-11-09 |
| 2021-03-31 | $133.88M 10-Q · filed 2022-11-09 |
| 2020-12-31 | $172.09M 10-K · filed 2024-03-15 |
| 2020-09-30 | $120.25M 10-Q · filed 2021-11-15 |
| 2020-06-30 | $136.21M 10-Q · filed 2021-11-15 |
| 2020-03-31 | $156.12M 10-Q · filed 2021-11-15 |
| 2019-12-31 | $130.35M 10-K · filed 2022-03-09 |
| 2019-09-30 | $146.20M 10-Q · filed 2020-11-12 |
| 2019-06-30 | -$34.94M 10-Q · filed 2020-11-12 |
| 2019-03-31 | -$23.05M 10-Q · filed 2020-11-12 |
| 2018-12-31 | -$17.31M 10-K · filed 2021-03-09 |
| 2018-09-30 | -$76.00K 10-Q · filed 2019-11-06 |
| 2018-06-30 | -$10.00K 10-Q · filed 2019-11-06 |
| 2018-05-02 | $0.00 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |